

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1: Name and Address of Reporting Issuer

Doseology Sciences Inc. (the “**Company**”)
Suite 305, 9-3151 Lakeshore Rd.
Kelowna, BC V1W 3S9

Item 2: Date of Material Change

September 12, 2024.

Item 3: News Release

A news release was issued and disseminated September 12, 2024 and filed on SEDAR+ at www.sedarplus.ca.

Item 4: Summary of Material Changes

The Company announced director and officer changes and option grants. See item 5 for further details.

Item 5: Full Description of Material Change

The Company announced key leadership appointments and a major expansion in its retail presence. Christopher P. Cherry has been appointed Interim CEO while maintaining his role as CFO, and both Zara Kanji and Cary Alexander Kazemi have joined the board of directors.

With over 15 years of experience in corporate accounting and auditing, Mr. Cherry brings a strong financial background to guide Doseology’s growth. His expertise from previous roles at various public companies and audit work with KPMG and Davidson and Co. LLP ensures the company’s continued financial stability.

Zara Kanji, founder of Zara Kanji & Associates, brings deep knowledge in financial reporting, taxation, and compliance. A Chartered Professional Accountant, Ms. Kanji has extensive experience working with both private and public companies, and her expertise will play a crucial role in supporting Doseology’s financial governance as the company scales.

In addition to her accounting practice, Ms. Kanji has held leadership roles as a director and officer for several publicly listed companies, providing key insights into financial governance and compliance. A Chartered Professional Accountant in British Columbia and Canada for over a decade, she holds a Bachelor of Technology in Accounting and a Diploma in Corporate Finance from the British Columbia Institute of Technology.

Cary Alexander Kazemi brings a wealth of international finance experience to the team, making him a key asset to Doseology’s strategic leadership. With a strong background in high-growth startups within the cannabis and plant science sectors, along with a deep passion for biotech and alternative medicine, Mr. Kazemi’s expertise aligns seamlessly with Doseology’s vision. A finance graduate from the University of Texas at Austin, Mr. Kazemi has been a licensed financial advisor, holding Series 7 and 66 licenses, and began his career with a two-year placement at Merrill Lynch within his family’s office.

Following his tenure at Merrill Lynch, Mr. Kazemi returned to the film industry, acting in projects across North America and Asia. He then leveraged his finance

expertise by successfully investing in independent film productions in Hollywood. His dedication to healthcare innovation has led him to support transformative initiatives like Doseology, as well as cannabis startups such as Jeeters, Bloom, and Tyson 2.0. Today, Mr. Kazemi continues to work closely with leaders in life sciences, technology, and consumer goods, driving innovation and meaningful change across industries.

As part of the leadership changes, Doseology has granted 80,000 incentive stock options to select directors, exercisable at \$0.40 over a five-year term. The Company also announces the departure of Shawn Balaghi as interim CEO and director, effective immediately, and thanks him for his contributions.

Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

Not applicable.

Item 8: Executive Officer

For further information, please contact:

Daniel Vice, Co-Founder and Director
Investor Relations: investor@doseology.com
General Inquiries: hello@doseology.com
Telephone: +1 825-800-0115

Item 9: Date of Report

September 12, 2024.